Imugene Limited

ASX:IMU.AX

0.05 (AUD) • At close November 12, 2024
Bedrijfsnaam Imugene Limited
Symbool IMU.AX
Munteenheid AUD
Prijs 0.048
Beurswaarde 357,038,880
Dividendpercentage 0%
52-weken bereik 0.043 - 0.13
Industrie Biotechnology
Sector Healthcare
CEO Ms. Leslie Chong
Website https://www.imugene.com

An error occurred while fetching data.

Over Imugene Limited

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer.

Vergelijkbare Aandelen

Nanosonics Limited logo

Nanosonics Limited

NAN.AX

3.32 AUD

Australian Clinical Labs Limited logo

Australian Clinical Labs Limited

ACL.AX

3.59 AUD

Telix Pharmaceuticals Limited logo

Telix Pharmaceuticals Limited

TLX.AX

23.47 AUD

Integral Diagnostics Limited logo

Integral Diagnostics Limited

IDX.AX

3.13 AUD

PolyNovo Limited logo

PolyNovo Limited

PNV.AX

2.06 AUD

Clinuvel Pharmaceuticals Limited logo

Clinuvel Pharmaceuticals Limited

CUV.AX

13.63 AUD

Regis Healthcare Limited logo

Regis Healthcare Limited

REG.AX

6.65 AUD

Oceania Healthcare Limited logo

Oceania Healthcare Limited

OCA.AX

0.665 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)